News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aradigm Corporation (ARDM) Awarded National Institutes of Health (NIH) Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections With Pulmaquin and Lipoquin


8/1/2013 9:41:32 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAYWARD, Calif.--(BUSINESS WIRE)--The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous mycobacteria infections with Aradigm’s inhaled liposomal ciprofloxacin products Pulmaquin® and Lipoquin®. The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Dr. Luiz Bermudez at the Oregon State University, Corvallis, will lead the laboratory research as a part of the consortium funded by this grant of approximately $278,000.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES